192. Cockayne syndrome Clinical trials / Disease details
Clinical trials : 4 / Drugs : 7 - (DrugBank : 3) / Drug target gene : 1 - Drug target pathways : 51
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR1900026719 | 2019-11-01 | 2019-10-19 | Clinical study for combined application of vitamin C and quercetin in the treatment of Cockayne's syndrome | Clinical study for combined application of vitamin C and quercetin in the treatment of Cockayne's syndrome | Cockayne's syndrome | test group:Vitamin C and Quercetin; | The First Medical Center of PLA General Hospital | NULL | Pending | 6 | 13 | Both | test group:20; | China | |
| 2 | NCT02960997 (ClinicalTrials.gov) | May 2016 | 15/6/2016 | Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study | A Prospective, Double-Blind, Cross-Over, Pilot Study to Assess Safety and Efficacy of Topical Sirolimus 2% in the Treatment of Plantar Blistering in Patients With Epidermolysis Bullous Simplex (EBS) | Epidermolysis Bullosa Simplex;Epidermolysis Bullosa Simplex Kobner;Weber-Cockayne Syndrome | Drug: Sirolimus, 2%;Drug: Vehicle | Stanford University | NULL | Active, not recruiting | 4 Years | N/A | All | 8 | Phase 2 | United States |
| 3 | NCT03016715 (ClinicalTrials.gov) | May 2016 | 9/1/2017 | Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study | A Prospective, Double-Blind, Cross-Over, Pilot Study to Assess Safety and Efficacy of Topical Sirolimus 2% in the Treatment of Plantar Blistering in Patients With Epidermolysis Bullous Simplex (EBS) | Epidermolysis Bullosa Simplex;Epidermolysis Bullosa Simplex Kobner;Weber-Cockayne Syndrome | Drug: Sirolimus 2%;Drug: Vehicle | Premier Specialists, Australia | NULL | Recruiting | 5 Years | N/A | All | 8 | Phase 2 | Australia |
| 4 | NCT01142154 (ClinicalTrials.gov) | June 2010 | 20/5/2010 | Pharmacokinetics and Safety Study of Single and Multiple Oral Doses Prodarsan™ in Patients With Cockayne Syndrome | A Phase I/II Crossover Study To Evaluate and Compare the Pharmacokinetics of a Single IV Dose of D-Mannitol (Osmitrol®10%) to Single and Multiple, Escalating Doses of Liquid, Oral Prodarsan™ in Patients With Cockayne Syndrome | Cockayne Syndrome | Drug: Prodarsan | DNage B.V. | NULL | Completed | 2 Years | 10 Years | Both | 5 | Phase 1/Phase 2 | United States |